VEGFB and metabolic dysfunction-associated steatotic liver disease: In a recent study using diabetic and NAFLD-induced mouse models, treatment with anti-VEGFB for long periods (2 months) prevented NAFLD development by blocking white adipose tissue lipolysis (Falkevall et al., 2023).